Stay updated with breaking news from John Lambert. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cancer is estimated to cost nearly US$1 trillion worldwide every year, but a small group of ASX biotech stocks is working to change that.
George will replace Jeff Carter, who is stepping down from the role after being the company’s CFO for more than eight years.
Amplia Therapeutics Ltd (ASX:ATX) is developing FAK inhibitors for cancer and fibrosis purposes with CEO and managing director John Lambert charting...
FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus on pancreatic and ovarian cancer.
A new approach to 'prime' the tumor environment may improve how effective chemotherapy is for pancreatic ductal adenocarcinoma, one of the most aggressive forms of pancreatic cancer.